582 related articles for article (PubMed ID: 2784998)
21. Extrahepatic expression of N-acetylator genotype in the inbred hamster.
Hein DW; Kirlin WG; Ogolla F; Trinidad A
Drug Metab Dispos; 1987; 15(1):68-73. PubMed ID: 2881761
[TBL] [Abstract][Full Text] [Related]
22. Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: identity with arylhydroxamic acid N,O-acyltransferase and N-hydroxyarylamine O-acetyltransferase.
Mattano SS; Land S; King CM; Weber WW
Mol Pharmacol; 1989 May; 35(5):599-609. PubMed ID: 2725469
[TBL] [Abstract][Full Text] [Related]
23. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
24. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions.
Hein DW; Doll MA; Rustan TD; Ferguson RJ
Cancer Res; 1995 Aug; 55(16):3531-6. PubMed ID: 7627960
[TBL] [Abstract][Full Text] [Related]
25. The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype.
Flammang TJ; Yamazoe Y; Guengerich FP; Kadlubar FF
Carcinogenesis; 1987 Dec; 8(12):1967-70. PubMed ID: 3677322
[TBL] [Abstract][Full Text] [Related]
26. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens.
Fretland AJ; Doll MA; Gray K; Feng Y; Hein DW
Toxicol Appl Pharmacol; 1997 Feb; 142(2):360-6. PubMed ID: 9070359
[TBL] [Abstract][Full Text] [Related]
27. Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6.A-NatS slow acetylator congenic mice.
Chung JG; Levy GN; Weber WW
Drug Metab Dispos; 1993; 21(6):1057-63. PubMed ID: 7905384
[TBL] [Abstract][Full Text] [Related]
28. Inheritance of acetylator genotype-dependent arylamine N-acetyltransferase in hamster bladder cytosol.
Hein DW; Kirlin WG; Yerokun T; Trinidad A; Ogolla F
Carcinogenesis; 1987 May; 8(5):647-52. PubMed ID: 3581423
[TBL] [Abstract][Full Text] [Related]
29. 4-Aminobiphenyl downregulation of NAT2 acetylator genotype-dependent N- and O-acetylation of aromatic and heterocyclic amine carcinogens in primary mammary epithelial cell cultures from rapid and slow acetylator rats.
Jefferson FA; Xiao GH; Hein DW
Toxicol Sci; 2009 Jan; 107(1):293-7. PubMed ID: 18842621
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen inhibits arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60 cells.
Lu KH; Lin KL; Hsia TC; Hung CF; Chou MC; Hsiao YM; Chung JG
Res Commun Mol Pathol Pharmacol; 2001; 109(5-6):319-31. PubMed ID: 12889515
[TBL] [Abstract][Full Text] [Related]
31. Polymorphic acetylation of arylamines and DNA-adduct formation.
Weber WW; Levy GN; Martell KJ
Princess Takamatsu Symp; 1990; 21():119-26. PubMed ID: 2134671
[TBL] [Abstract][Full Text] [Related]
32. Acetyl coenzyme A-dependent metabolic activation of N-hydroxy-3,2'-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxy arylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acyltransferases.
Flammang TJ; Kadlubar FF
Carcinogenesis; 1986 Jun; 7(6):919-26. PubMed ID: 3708755
[TBL] [Abstract][Full Text] [Related]
33. Effects of vitamin C on arylamine N-acetyltransferase activity in human liver tumor cells.
Wu LT; Chung JG
Anticancer Res; 1998; 18(5A):3481-6. PubMed ID: 9858928
[TBL] [Abstract][Full Text] [Related]
34. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
Grant DM; Mörike K; Eichelbaum M; Meyer UA
J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
[TBL] [Abstract][Full Text] [Related]
35. Arylamine N-acetyltransferase activity of the human placenta.
Derewlany LO; Knie B; Koren G
J Pharmacol Exp Ther; 1994 May; 269(2):756-60. PubMed ID: 8182542
[TBL] [Abstract][Full Text] [Related]
36. Ellagic [correction of ellagica] acid inhibits arylamine N-acetyltransferase activity and DNA adduct formation in human bladder tumor cell lines (T24 and TSGH 8301).
Lin SS; Hung CF; Tyan YS; Yang CC; Hsia TC; Yang MD; Chung JG
Urol Res; 2001 Dec; 29(6):371-6. PubMed ID: 11828989
[TBL] [Abstract][Full Text] [Related]
37. Acetyl transferase-mediated metabolic activation of N-hydroxy-4-aminobiphenyl by human uroepithelial cells.
Frederickson SM; Hatcher JF; Reznikoff CA; Swaminathan S
Carcinogenesis; 1992 Jun; 13(6):955-61. PubMed ID: 1600616
[TBL] [Abstract][Full Text] [Related]
38. Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2'-dimethyl-4-aminobiphenyl.
Feng Y; Fretland AJ; Rustan TD; Jiang W; Becker WK; Hein DW
Toxicol Appl Pharmacol; 1997 Nov; 147(1):56-62. PubMed ID: 9356307
[TBL] [Abstract][Full Text] [Related]
39. In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice.
Sugamori KS; Brenneman D; Grant DM
Drug Metab Dispos; 2006 Oct; 34(10):1697-702. PubMed ID: 16815960
[TBL] [Abstract][Full Text] [Related]
40. Tissue distribution of N-acetyltransferase 1 and 2 catalyzing the N-acetylation of 4-aminobiphenyl and O-acetylation of N-hydroxy-4-aminobiphenyl in the congenic rapid and slow acetylator Syrian hamster.
Hein DW; Doll MA; Nerland DE; Fretland AJ
Mol Carcinog; 2006 Apr; 45(4):230-8. PubMed ID: 16482518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
